CBG and Attention: A Double-Blind, Randomized, Placebo-Controlled Trial Examining the Effects of Cannabigerol on Indicators of Attention-Deficit/Hyperactivity Disorder
University of Arkansas, Fayetteville
Summary
The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.
Eligibility
- Age range
- 18–55 years
- Sex
- All
- Healthy volunteers
- Yes
1. Between 18 and 55-years-old. 2. BMI between 18 and 35 kg/m2. 3. Score a 4 or above on the Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Part A. 4. Meet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND. 5. Are not pregnant or currently breastfeeding. 6. Have no history of significant allergic condition, hypersensitivity, or allergic reactions to cannabis, cannabinoid medications, hemp products, medium chain triglyceride oil, or peppermint. 7. Have not used CBG or any other cannabinoid products in the past 30 days. 8. Willing…
Interventions
- DrugCannabigerol
1 mL of 80mg Cannabigerol once during experimental session
- OtherPlacebo
1 mL of placebo once during experimental session
Location
- University of ArkansasFayetteville, Arkansas